Annovis Bio Reports Increased Net Loss of $17.6 Million in Q1 2026

Annovis Bio, Inc. reported a significant increase in its net loss for the first quarter of 2026, amounting to $17.6 million, compared to a net loss of $5.5 million for the same period in 2025. The company's total operating expenses rose to $18.0 million, up from $6.3 million year-over-year, primarily driven by a substantial increase in research and development costs, which surged to $16.7 million from $5.0 million. This increase reflects the company's ongoing clinical trials, particularly the pivotal Phase 3 study for its lead product candidate, buntanetap, aimed at treating neurodegenerative diseases such as Alzheimer's and Parkinson's.

In terms of financial position, Annovis reported cash and cash equivalents of $14.2 million as of March 31, 2026, a decrease from $19.5 million at the end of 2025. The company's total assets also fell to $16.2 million from $21.1 million, while total liabilities increased significantly to $13.1 million from $4.2 million, largely due to a rise in accounts payable and accrued expenses. The accumulated deficit reached $181.3 million, indicating the ongoing financial challenges faced by the company as it continues to invest heavily in its clinical programs without generating revenue.

Strategically, Annovis has been active in its clinical development efforts, currently conducting two major studies: a Phase 3 trial for early Alzheimer's patients and an open-label extension study for Parkinson's disease patients. The Phase 3 trial is expected to complete patient screening by mid-May 2026, with full enrollment anticipated shortly thereafter. The company is also refining a proposed protocol for a study in Parkinson's disease dementia, contingent on securing additional funding. These developments are critical as they aim to position Annovis for potential regulatory submissions in the near future.

Operationally, the company has seen a notable increase in its employee headcount, reflecting its expansion efforts to support clinical trials and administrative functions. As of the latest filing, Annovis has treated over 1,300 patients in its clinical studies, underscoring its commitment to advancing its product candidates. However, the company acknowledges that it will need to raise additional capital to sustain its operations and fund ongoing clinical trials, as its current cash reserves are not sufficient to cover expenses for the next 12 months.

Looking ahead, Annovis Bio anticipates continued losses as it ramps up its clinical development programs. The company has expressed substantial doubt regarding its ability to continue as a going concern without raising additional capital. Management plans to explore various financing options, including equity offerings and potential collaborations, to secure the necessary funds to support its operations and clinical initiatives. The outcome of these efforts will be crucial for the company's future viability and success in the competitive biopharmaceutical landscape.